MDS

1:48
Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
Saar Gill
1:12
Hypomethylating agents for low risk MDS
Eunice Wang
1:32
IDH inhibitors for AML and MDS
Eunice Wang
3:41
Computational methods are the future of biological research
Dominique Bonnet
3:38
A new set of treatment options for low-risk MDS
Esther Oliva
1:44
A worldwide Phase III trial treating AML with pracinostat
Guillermo Garcia-Manero
3:36
Highlights: ASCO 2018 oral abstract presentations
Guillermo Garcia-Manero
0:47
Targeting DNA methylation as a therapeutic target in multiple myeloma
Benjamin Barwick
0:52
Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab
3:55
The molecular mechanisms of epigenetic therapies: LTRs and TINATs
Christoph Plass
1:43
The drugs being used to treat newly diagnosed AML patients
Mark Levis
1:41
The future of AML and MDS diagnosis and treatment
Stéphane de Botton
1:02
Bispecific agents: the future of AML and MDS treatment?
John DiPersio
0:52
HARMONY: a collaboration between 51 partners
Lars Bullinger
5:47
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
Aziz Nazha
2:39
Film-coated tablet deferasirox formulation for thalassemia and myelodysplastic syndromes (MDS)
Ali Taher
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals